A history of late and very late stent thrombosis is not associated with increased activation of the contact system, a case control study.
BACKGROUND
The pathophysiological pathways resulting in Late Stent Thrombosis (LST) remain uncertain. Findings from animal studies indicate a role of the intrinsic coagulation pathway in arterial thrombus formation, while clinical studies support an association with ischemic cardiovascular disease. It is currently unknown whether differences in the state of the contact system might contribute to the risk of LST or Very Late Stent Thrombosis (VLST). We assessed the relation between levels of several components involved in the contact system and a history of LST and VLST, termed (V)LST in a cohort of 20 patients as compared to a matched control group treated with PCI.


RESULTS
Activated factor XII (FXIIa), FXII zymogen (FXII), FXIIa-C1-esterase inhibitor (C1-inhibitor), Kallikrein-C1-inhibitor, FXIa-C1-inhibitor and FXIa-alpha1-antitrypsin (AT-inhibitor) complexes were measured by Enzyme-linked immunosorbent assy (ELISA) methodology.Cases and controls showed similar distributions in sex, age, baseline medications and stent type. Patients with a history of (V)LST had a significantly greater stent burden and a higher number of previous myocardial infarctions than the control patients.There were no significant between-group differences in the plasma levels of the components of the contact system.


CONCLUSIONS
In a cohort of patients with a history of (V)LST, we did not observe differences in the activation state of the intrinsic coagulation system as compared to patients with a history of percutaneous coronary intervention without stent thrombosis.
Pönitz
Volker
V
Institute of Medicine, University of Bergen, Bergen, Norway. povo@sus.no.
Govers-Riemslag
José W
JW
Ten Cate
Hugo
H
van Oerle
Rene
R
Brügger-Andersen
Trygve
T
Grundt
Heidi
H
Næsgaard
Patrycja
P
Pritchard
David
D
Larsen
Alf I
AI
Nilsen
Dennis W
DW
N Engl J Med. 2007 Mar 8;356(10):1030-9
17296823
Blood. 2006 Dec 15;108(13):4045-51
16931632
N Engl J Med. 2007 Mar 8;356(10):989-97
17296825
J Am Coll Cardiol. 2006 Jul 4;48(1):193-202
16814667
J Thromb Haemost. 2008 Feb;6(2):291-6
18021303
Int J Cardiol. 2006 May 24;109(3):398-401
16102858
J Thromb Haemost. 2009 Feb;7(2):277-87
19054318
J Am Coll Cardiol. 2005 Jun 7;45(11):1753-6
15936600
J Thromb Haemost. 2007 Jun;5(6):1143-8
17388965
Circulation. 2007 Oct 23;116(17):1952-65
17965406
Blood. 1977 Oct;50(4):611-7
561632
Circulation. 2006 Feb 28;113(8):1108-13
16490815
J Exp Med. 1971 Apr 1;133(4):696-712
4251126
J Clin Invest. 1983 May;71(5):1450-6
6304147
Circulation. 2007 May 8;115(18):2426-34
17485593
Am J Cardiol. 2005 Jun 15;95(12):1469-72
15950574
Biochemistry. 1980 Apr 1;19(7):1330-8
6155942
Circulation. 2000 Dec 5;102(23):2816-22
11104738
Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2103-6
9351378
Thromb Haemost. 1998 Jan;79(1):14-8
9459314
Am Heart J. 2004 Feb;147(2):260-6
14760323
Blood. 1986 Jun;67(6):1731-7
3486686
Circulation. 2000 Oct 24;102(17):2058-62
11044420
Am J Hematol. 1978;4(4):409-17
362910
Circulation. 2007 May 1;115(17):2344-51
17470709
N Engl J Med. 2007 Mar 8;356(10):998-1008
17296824
J Thromb Haemost. 2007 Sep;5(9):1896-903
17723129
J Exp Med. 2005 Jul 18;202(2):271-81
16009717
Lancet. 2007 Feb 24;369(9562):667-78
17321312
Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11969-72
1465426
J Am Coll Cardiol. 2007 Jul 10;50(2):119-27
17616295
Circulation. 2004 Feb 17;109(6):701-5
14744976
Thromb Haemost. 1998 Oct;80(4):686-91
9798991
Clin Chem. 2001 Mar;47(3):418-25
11238291
Thromb Haemost. 2000 Jun;83(6):874-81
10896241
Eur Heart J. 2005 Jun;26(12):1180-7
15728650